GT Apeiron Therapeutics

China
unknown
Sign in to unlock
unknown
Stage

About

GT Apeiron Therapeutics is a clinical stage small molecule biotech company developing biomarker-driven cancer therapeutics, including a PRMT5 inhibitor in Phase 1 clinical trials and a KIF18A inhibitor with a differentiated profile.

Explore GT Apeiron Therapeutics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing